All In Biotech

Drug Trial Radar · NCT05453799

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

A Phase II, Multicenter Study of XmAb20717 in Patients With Metastatic Anaplastic Thyroid Cancer With an Exploratory Cohort in Aggressive Hurthle Cell Thyroid Cancer

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

54

Planned (sponsor's estimate)

Start

Jul 21, 2022

Primary completion

Oct 31, 2023

Study completion Sep 5, 2030

Sponsor

Lead sponsor
Northwestern UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jul 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests whether vudalimab works to shrink tumors in patients with anaplastic thyroid cancer or hurthle cell thyroid cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as vudalimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Locally Advanced Thyroid Gland Anaplastic Carcinoma
  • Metastatic Thyroid Gland Anaplastic Carcinoma
  • Metastatic Thyroid Gland Oncocytic Carcinoma

Interventions

  • VudalimabDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to 5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Northwestern University

    Chicago, Illinois

  • M D Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.